ArticleCancer research communications2023

Toll-like Receptor Signaling-deficient Cells Enhance Antitumor Activity of Cell-based Immunotherapy by Increasing Tumor Homing.

Alvaro Morales-Molina et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.